Free Trial Information
BioCentury | Oct 15, 2012
Clinical News

Herceptin trastuzumab: Phase III data

Genentech Inc. , South San Francisco, Calif. Chugai Pharmaceutical Co. Ltd. (Tokyo:4519), Tokyo, Japan F. Hoffmann-La Roche Ltd. (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: Herceptin trastuzumab ( RG597 ) Business: Cancer Molecular target: Epidermal growth factor receptor 2 (EGFR2)...
Read More
BioCentury | Sep 27, 2004
Company News

Inyx, Phares Technology BV deal

...IYXI completed its acquisition of a platform technology from Phares subsidiary Phares Drug Delivery AG (Muttenz, Switzerland) that IYXI...
...substances to mucosal membranes. Financial terms were not disclosed. Inyx Inc. (IYXI), New York, N.Y. Phares...
Read More
BioCentury | May 6, 2002
Emerging Company Profile

Corporate Profile

...by Sanjay Kakkar, Canasta Group Ltd. and Thrombosis Research Institute Corporate partners: Covance Inc. , Phares...
Read More
Items per page:
1 - 3 of 3
BioCentury | Oct 15, 2012
Clinical News

Herceptin trastuzumab: Phase III data

Genentech Inc. , South San Francisco, Calif. Chugai Pharmaceutical Co. Ltd. (Tokyo:4519), Tokyo, Japan F. Hoffmann-La Roche Ltd. (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: Herceptin trastuzumab ( RG597 ) Business: Cancer Molecular target: Epidermal growth factor receptor 2 (EGFR2)...
Read More
BioCentury | Sep 27, 2004
Company News

Inyx, Phares Technology BV deal

...IYXI completed its acquisition of a platform technology from Phares subsidiary Phares Drug Delivery AG (Muttenz, Switzerland) that IYXI...
...substances to mucosal membranes. Financial terms were not disclosed. Inyx Inc. (IYXI), New York, N.Y. Phares...
Read More
BioCentury | May 6, 2002
Emerging Company Profile

Corporate Profile

...by Sanjay Kakkar, Canasta Group Ltd. and Thrombosis Research Institute Corporate partners: Covance Inc. , Phares...
Read More
Items per page:
1 - 3 of 3